Drug intelligence / Profile preview

Entella

Development stage: Unknown
Lead developer: Espad Pharmed
Administration: Dermal, Subcutaneous, Intracutaneous

Overview

Entella is a hyaluronic acid-based dermal filler developed and manufactured by Espad Pharmed for aesthetic and cosmetic applications. It is specifically indicated for soft-tissue augmentation, wrinkle correction, and facial volumization. Administered via dermal, subcutaneous, or intracutaneous injection, Entella works by physically filling space within the tissue and binding water molecules to restore lost volume and smooth facial contours. As a cross-linked hyaluronic acid gel, it provides a non-surgical option for addressing age-related facial changes and enhancing aesthetic features. The product is part of a broader portfolio of aesthetic injectables produced by Espad Pharmed, which focuses on cosmetic medicine rather than traditional therapeutic pharmaceutical development.

Brand names: Entella

Beyond the preview

Go deeper on Entella.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Entella.

Explore the full profile